JNJ-56022473: Phase II started

Johnson & Johnson’s Janssen Biotech Inc. unit began an open-label, international Phase II trial to evaluate 9 mg/kg IV JNJ-56022473 plus IV Dacogen decitabine in 126 patients who are ineligible for intensive chemotherapy. The first part will confirm the recommended dose of JNJ-56022473. In the first 28-day cycle, patients will receive JNJ-56022473 on day 1. Starting with the second cycle, patients will receive JNJ-56022473 on days 8 and 22 plus Dacogen on days 1-5. The second part will compare JNJ-56022473 on days 8 and 22 plus Dacogen on days 1-5 vs. Dacogen alone. ...